BCR::ABL1 enhances cell survival in CML by activating several signaling pathways, including mitogen-activated protein kinase (MAPK), AKT, and STAT5, which were downregulated with the TKI treatment [32–34]. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.